Phio Pharmaceuticals Corp. (PHIO)
NASDAQ$1.29
Market Cap
$6.16M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
400 of 924
Rank in Industry
234 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
PHIO Insider Trading Activity
PHIO Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $1,490 | 2 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Bitterman Robert J | President & CEO | 2 | $1,490 | 0 | $0 | $1,490 |
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that …
Insider Activity of Phio Pharmaceuticals Corp.
Over the last 12 months, insiders at Phio Pharmaceuticals Corp. have bought $1,490 and sold $0 worth of Phio Pharmaceuticals Corp. stock.
On average, over the past 5 years, insiders at Phio Pharmaceuticals Corp. have bought $10,671 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Bitterman Robert J (President & CEO) — $1,490.
The last purchase of 1,000 shares for transaction amount of $740 was made by Bitterman Robert J (President & CEO) on 2024‑06‑07.
List of Insider Buy and Sell Transactions, Phio Pharmaceuticals Corp.
| 2024-06-07 | Bitterman Robert J | President & CEO | 1,000 0.0216% | $0.74 | $740 | -58.12% | ||
| 2024-06-06 | Bitterman Robert J | President & CEO | 1,000 0.0218% | $0.75 | $750 | -58.37% | ||
| 2024-02-26 | Bitterman Robert J | President & CEO | 2,500 0.0539% | $0.91 | $2,275 | -60.89% | ||
| 2023-07-01 | Bitterman Robert J | President & CEO | 1,000 0.0866% | $2.84 | $2,840 | -48.79% | ||
| 2023-06-30 | Bitterman Robert J | President & CEO | 1,000 0.0879% | $2.88 | $2,880 | -67.89% | ||
| 2023-06-14 | Ferrara Robert L | director | 2,000 0.1723% | $3.10 | $6,200 | -69.59% | ||
| 2022-12-14 | Bitterman Robert J | Interim Executive Chairman | 2,000 0.015% | $0.39 | $780 | -34.24% | ||
| 2022-12-07 | Bitterman Robert J | Interim Executive Chairman | 2,000 0.0149% | $0.39 | $780 | -31.77% | ||
| 2022-12-05 | Bitterman Robert J | Interim Executive Chairman | 2,000 0.0156% | $0.43 | $860 | -34.98% | ||
| 2022-12-02 | Ferrara Robert L | director | 5,000 0.0377% | $0.41 | $2,041 | -32.25% | ||
| 2022-11-29 | Bitterman Robert J | Interim Executive Chairman | 215 0.0016% | $0.40 | $86 | -31.88% | ||
| 2022-11-25 | Bitterman Robert J | Interim Executive Chairman | 2,500 0.019% | $0.42 | $1,050 | -31.05% | ||
| 2022-11-23 | Ferrara Robert L | director | 2,000 0.0147% | $0.41 | $820 | -31.71% | ||
| 2022-11-16 | Bitterman Robert J | Interim Executive Chairman | 1 – | $1,750.00 | $1,750 | -30.57% | ||
| 2021-08-16 | Dispersyn Gerrit | President & CEO | 6,000 0.0446% | $1.63 | $9,780 | -43.62% | ||
| 2021-03-04 | Dispersyn Gerrit | President & CEO | 1,953 0.0185% | $2.56 | $5,000 | -26.88% | ||
| 2021-03-03 | Dispersyn Gerrit | President & CEO | 2,500 0.0241% | $3.03 | $7,575 | -36.39% | ||
| 2021-03-03 | Ferrara Robert L | director | 682 0.0068% | $3.15 | $2,148 | -36.39% | ||
| 2020-08-19 | Dispersyn Gerrit | President & CEO | 2,000 0.0345% | $2.50 | $5,000 | -8.96% | ||
| 2017-10-02 | CAUWENBERGH GEERT | President & CEO | 10,000 0.0428% | $0.45 | $4,475 | -35.40% |
Total: 92
*Gray background shows transactions not older than one year
*Some uncertain data for Preferred Stock share type transactions are shown in italics; for actual data please follow the link
Insider Historical Profitability
<0.0001%
| Bitterman Robert J | President & CEO | 20990 0.4394% | $27,077.10 | 14 | 0 | <0.0001% |
| Advanced RNA Technologies, LLC | 1221723 25.5759% | $1.58M | 1 | 0 | ||
| CAUWENBERGH GEERT | President & CEO | 142583 2.9849% | $183,932.07 | 60 | 0 | |
| Dispersyn Gerrit | President & CEO | 95281 1.9946% | $122,912.49 | 5 | 0 | <0.0001% |
| Ferrara Robert L | director | 6000 0.1256% | $7,740.00 | 4 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$18,881,323 | 88 | -48.96% | $4.47M | |
$1,226,605 | 43 | -21.28% | $7.98M | |
$296,936 | 37 | -18.12% | $4M | |
$523,320 | 24 | 94.37% | $7.01M | |
$31,129 | 22 | -11.96% | $6.19M |
PHIO Institutional Investors: Active Positions
| Increased Positions | 9 | +150% | 151,171 | +530.31% |
| Decreased Positions | 2 | -33.33% | 25,631 | -89.91% |
| New Positions | 7 | New | 146,951 | New |
| Sold Out Positions | 2 | Sold Out | 25,631 | Sold Out |
| Total Postitions | 13 | +116.67% | 154,046 | +440.4% |
PHIO Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Citadel Advisors Llc | $63.00 | 0.89% | 44,526 | +44,526 | New | 2024-12-31 |
| Hrt Financial Lp | $60.00 | 0.85% | 42,338 | +42,338 | New | 2024-12-31 |
| Virtu Financial Llc | $58.00 | 0.82% | 40,910 | +40,910 | New | 2024-12-31 |
| Cetera Investment Advisers | $18.00 | 0.26% | 13,000 | +13,000 | New | 2024-12-31 |
| Morgan Stanley | $8.00 | 0.12% | 5,911 | +5,911 | New | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $7.00 | 0.09% | 4,682 | +3,508 | +298.81% | 2024-12-31 |
| Ubs Group Ag | $3.00 | 0.05% | 2,397 | +712 | +42.26% | 2024-12-31 |
| Barclays Plc | $0 | <0.01% | 203 | +203 | New | 2024-12-31 |
| Sbi Securities Co., Ltd. | $0 | <0.01% | 63 | +63 | New | 2024-12-31 |
| Activest Wealth Management | $0 | 0% | 9 | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.